Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP924790.RAatRtWd1yUhw-6VbX_rcfgc8UQYlKP2HNL4hOAyHoThc130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP924790.RAatRtWd1yUhw-6VbX_rcfgc8UQYlKP2HNL4hOAyHoThc130_assertion type Assertion NP924790.RAatRtWd1yUhw-6VbX_rcfgc8UQYlKP2HNL4hOAyHoThc130_head.
- NP924790.RAatRtWd1yUhw-6VbX_rcfgc8UQYlKP2HNL4hOAyHoThc130_assertion description "[The combination of pegylated interferon (PEG-IFN), ribavirin (RBV) and a protease inhibitor (PI) has been approved in summer 2011 for the treatment of genotype 1 (G1) hepatitis C virus (HCV)-infected patients, with a substantially improved efficacy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP924790.RAatRtWd1yUhw-6VbX_rcfgc8UQYlKP2HNL4hOAyHoThc130_provenance.
- NP924790.RAatRtWd1yUhw-6VbX_rcfgc8UQYlKP2HNL4hOAyHoThc130_assertion evidence source_evidence_literature NP924790.RAatRtWd1yUhw-6VbX_rcfgc8UQYlKP2HNL4hOAyHoThc130_provenance.
- NP924790.RAatRtWd1yUhw-6VbX_rcfgc8UQYlKP2HNL4hOAyHoThc130_assertion SIO_000772 21930731 NP924790.RAatRtWd1yUhw-6VbX_rcfgc8UQYlKP2HNL4hOAyHoThc130_provenance.
- NP924790.RAatRtWd1yUhw-6VbX_rcfgc8UQYlKP2HNL4hOAyHoThc130_assertion wasDerivedFrom befree-2016 NP924790.RAatRtWd1yUhw-6VbX_rcfgc8UQYlKP2HNL4hOAyHoThc130_provenance.
- NP924790.RAatRtWd1yUhw-6VbX_rcfgc8UQYlKP2HNL4hOAyHoThc130_assertion wasGeneratedBy ECO_0000203 NP924790.RAatRtWd1yUhw-6VbX_rcfgc8UQYlKP2HNL4hOAyHoThc130_provenance.